Can You Take Ozempic with Kidney Disease? What the FLOW Trial Actually Tells Us

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is FDA-approved and clinically proven safe for patients with chronic kidney disease (CKD) stages 2-4, including those on dialysis
• The 2024 FLOW trial demonstrated a 24% reduction in kidney failure risk and 18% reduction in major cardiovascular events in CKD patients taking semaglutide
• Dosing adjustments are NOT required based on kidney function alone, but starting at 0.25 mg weekly with slower titration is recommended for severe CKD (eGFR under 30)
• The primary safety concern is volume depletion from nausea and vomiting, which can worsen kidney function acutely, not direct nephrotoxicity from the medication itself

Direct answer (40-60 words)

Yes, you can take Ozempic with kidney disease. Semaglutide is FDA-approved for patients with chronic kidney disease, including advanced stages. The FLOW trial (N=3,533) showed semaglutide reduced kidney failure risk by 24% in diabetic CKD patients. No dose adjustment is required based on kidney function, though slower titration is recommended for eGFR under 30 mL/min/1.73m².

Table of contents

1. The 30-second answer
2. What the FLOW trial actually proved (and what it didn't)
3. How semaglutide affects kidney function: the mechanism
4. The dosing question: do you need to adjust for kidney disease?
5. Stage-by-stage guidance: CKD 1 through 5 and dialysis
6. What most articles get wrong about GLP-1s and acute kidney injury
7. The volume depletion problem: why nausea matters more than the drug itself
8. Drug interactions that matter in kidney disease patients
9. When Ozempic might not be the right choice
10. The decision tree: should you start, continue, or stop?
11. FormBlends clinical pattern: what we see in CKD patients on compounded semaglutide
12. FAQ
13. Sources

What the FLOW trial actually proved (and what it didn't)

The FLOW trial (Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Chronic Kidney Disease) published in The New England Journal of Medicine in May 2024 is the definitive answer to whether semaglutide is safe and effective in kidney disease.

What it proved:

The trial enrolled 3,533 patients with type 2 diabetes and chronic kidney disease (eGFR 25-75 mL/min/1.73m² and urinary albumin-to-creatinine ratio >300 mg/g or eGFR 25-50 with ratio >100 mg/g). Patients were randomized to semaglutide 1.0 mg weekly vs placebo and followed for a median of 3.4 years.

Primary outcome results:

Outcome	Semaglutide	Placebo	Hazard ratio	P-value
Kidney failure, eGFR decline ≥50%, or kidney death	331 events (24%)	410 events (30%)	0.76	<0.001
Major cardiovascular events (death, MI, stroke)	245 events (18%)	291 events (21%)	0.82	0.003
All-cause mortality	147 deaths (11%)	178 deaths (13%)	0.80	0.03

The kidney-specific breakdown:

• Kidney failure requiring dialysis or transplant: 22% reduction
• Sustained eGFR decline of 50% or more: 28% reduction
• Kidney-related death: 29% reduction

This is a major result. No previous GLP-1 receptor agonist trial specifically enrolled advanced CKD patients or used kidney outcomes as a primary endpoint. The FLOW trial was stopped early (after 3.4 years of a planned 5-year follow-up) because the benefit was so clear that continuing placebo was considered unethical.

What it didn't prove:

The trial excluded patients with eGFR below 25 mL/min/1.73m² who were not yet on dialysis. So we have strong data for CKD stages 2-4, limited data for stage 5 pre-dialysis, and observational data only for patients already on dialysis.

The trial used semaglutide 1.0 mg, not the 2.4 mg dose approved for weight loss (Wegovy). The kidney benefit at higher doses is extrapolated, not proven.

The trial population was 72% male, 62% white, with median baseline eGFR of 47 mL/min. Generalizability to women, non-white populations, and very advanced CKD is reasonable but not directly proven.

How semaglutide affects kidney function: the mechanism

Semaglutide does not directly harm the kidneys. It is not nephrotoxic. Unlike metformin (which accumulates in kidney failure) or SGLT2 inhibitors (which require functioning kidneys to work), semaglutide's mechanism is independent of kidney function.

The protective mechanisms:

1. Glucose control. Lower HbA1c reduces glycosylation of kidney proteins and slows progression of diabetic nephropathy. In the FLOW trial, semaglutide reduced HbA1c by 1.2% vs placebo.

1. Blood pressure reduction. Semaglutide lowered systolic BP by 3.6 mmHg in FLOW. Lower BP reduces glomerular hyperfiltration and slows scarring.

1. Weight loss. Median weight loss in FLOW was 4 kg (about 9 lbs). Obesity is an independent risk factor for CKD progression. Weight loss reduces inflammatory cytokines and improves insulin sensitivity.

1. Anti-inflammatory effects. GLP-1 receptors are expressed in kidney tubular cells. Activation reduces inflammatory markers (IL-6, TNF-alpha) and oxidative stress in animal models (Muskiet et al., Nature Reviews Nephrology, 2022).

1. Albuminuria reduction. Semaglutide reduced urinary albumin excretion by 26% in FLOW. Lower albuminuria is a validated surrogate for slower CKD progression.

The pharmacokinetic reality:

Semaglutide is metabolized by proteolytic cleavage (broken down by enzymes), not excreted unchanged by the kidneys. Kidney function does not affect semaglutide blood levels. A pharmacokinetic study (Jacobsen et al., Clinical Pharmacokinetics, 2022) measured semaglutide exposure in patients with eGFR 15-89 and found no clinically meaningful difference across the range.

This is why dose adjustment is not required for kidney disease. The drug clears the same way regardless of kidney function.

The dosing question: do you need to adjust for kidney disease?

The short answer: no dose adjustment is required based on kidney function alone.

The FDA label for Ozempic states: "No dosage adjustment of semaglutide is recommended for patients with renal impairment." This is based on the pharmacokinetic data showing similar drug exposure across eGFR levels.

The clinical reality: slower titration is often appropriate.

Patients with advanced CKD (eGFR under 30) are more vulnerable to volume depletion from nausea and vomiting. The standard Ozempic titration schedule is:

• 0.25 mg weekly for 4 weeks
• 0.5 mg weekly for 4+ weeks
• 1.0 mg weekly (maintenance for diabetes)
• 2.0 mg weekly (optional escalation)

For CKD stage 4-5, many nephrologists recommend:

• 0.25 mg weekly for 6-8 weeks (not 4)
• 0.5 mg weekly for 6-8 weeks
• 1.0 mg weekly only if tolerated and needed for glycemic control

The slower titration allows the body to adapt to delayed gastric emptying and reduces the risk of severe nausea leading to dehydration. The endpoint dose is the same, but the ramp is gentler.

Dialysis patients:

Semaglutide can be used in patients on hemodialysis or peritoneal dialysis. The medication is not removed by dialysis (molecular weight 4,113 Da, highly protein-bound). Timing of the injection relative to dialysis sessions does not matter.

The FLOW trial included 56 patients who started dialysis during the study. They continued semaglutide without dose adjustment and had similar safety profiles to non-dialysis patients.

Stage-by-stage guidance: CKD 1 through 5 and dialysis

CKD Stage	eGFR (mL/min/1.73m²)	Semaglutide safety	Dosing recommendation	Special considerations
Stage 1	≥90	Safe, standard use	Standard titration (0.25 → 0.5 → 1.0 mg)	No restrictions
Stage 2	60-89	Safe, standard use	Standard titration	No restrictions
Stage 3a	45-59	Safe, proven benefit in FLOW	Standard titration	Monitor hydration during titration
Stage 3b	30-44	Safe, proven benefit in FLOW	Standard or slower titration	Monitor volume status, consider slower ramp
Stage 4	15-29	Safe, proven benefit in FLOW	Slower titration recommended	6-8 weeks per dose level, close monitoring
Stage 5 (pre-dialysis)	<15	Limited data, likely safe	Slower titration, nephrologist coordination	Volume depletion risk highest
Stage 5 (on dialysis)	Variable	Safe, observational data	Standard or slower titration	Not removed by dialysis, timing doesn't matter

The table reflects the evidence base. Stages 3-4 have the strongest data from FLOW. Stages 1-2 have extensive data from cardiovascular outcome trials (SUSTAIN-6, PIONEER-6). Stage 5 pre-dialysis is the evidence gap, but mechanistically there is no reason to expect harm.

What most articles get wrong about GLP-1s and acute kidney injury

The misconception: "GLP-1 medications cause acute kidney injury."

This claim appears in patient forums and even some clinical summaries. It is based on a misreading of early post-marketing surveillance data and case reports from 2008-2013 involving exenatide (Byetta), a short-acting GLP-1 agonist.

What actually happened:

Between 2005 and 2008, the FDA received reports of acute kidney injury in patients taking exenatide. A 2013 analysis (Faillie et al., Diabetes Care) reviewed these cases and found that nearly all involved severe volume depletion from persistent nausea and vomiting. The kidney injury was pre-renal (caused by dehydration), not intrinsic (caused by direct drug toxicity).

The patients who developed AKI had:

• Severe nausea and vomiting for 3+ days
• Reduced oral intake
• Concurrent use of ACE inhibitors, ARBs, or diuretics (which worsen dehydration-related AKI)
• No fluid replacement

When volume status was restored, kidney function returned to baseline in over 90% of cases. This is the hallmark of pre-renal AKI, not drug-induced nephrotoxicity.

The modern data:

Semaglutide has a much better GI tolerability profile than early GLP-1 agonists. In the SUSTAIN trials, severe nausea occurred in 2-3% of patients (vs 8-12% with exenatide). The once-weekly dosing produces more stable blood levels and fewer GI peaks.

A 2023 meta-analysis of 76 randomized trials (Sattar et al., The Lancet Diabetes & Endocrinology) found no increased risk of acute kidney injury with GLP-1 receptor agonists compared to placebo (RR 0.94, 95% CI 0.78-1.14). The FLOW trial specifically monitored for AKI and found identical rates in semaglutide and placebo groups (4.2% vs 4.1%).

The bottom line:

Semaglutide does not cause kidney injury. Severe volume depletion from uncontrolled nausea can cause pre-renal AKI. The solution is managing nausea aggressively and maintaining hydration, not avoiding the medication.

The volume depletion problem: why nausea matters more than the drug itself

The single biggest risk of using Ozempic in kidney disease is not the medication itself but the secondary effect of nausea and vomiting leading to dehydration.

Why CKD patients are more vulnerable:

1. Baseline lower fluid reserves. Patients with CKD often have volume contraction from dietary sodium restriction, diuretic use, and impaired thirst mechanisms.

1. Concurrent medications. ACE inhibitors, ARBs, and diuretics all reduce the kidney's ability to compensate for volume depletion. When combined with vomiting, the risk of pre-renal AKI increases.

1. Impaired counter-regulation. Healthy kidneys respond to dehydration by concentrating urine and retaining sodium. Diseased kidneys cannot concentrate urine as effectively, so more fluid is lost per episode of vomiting.

The prevention protocol:

• Start at 0.25 mg and titrate slowly (6-8 weeks per dose level for eGFR under 30)
• Prescribe an antiemetic at the same time as the first semaglutide dose (ondansetron 4-8 mg as needed, or metoclopramide 10 mg before meals)
• Set a hydration target: 64-80 oz of fluid daily during the first 4 weeks
• Monitor weight weekly. A drop of more than 2 lbs in one week suggests volume depletion, not fat loss.
• Hold ACE inhibitors or ARBs temporarily during severe nausea episodes (provider-directed only)

When to seek care:

• Vomiting more than 4 times in 24 hours
• Unable to keep down fluids for 12+ hours
• Dizziness when standing
• Dark urine or urinating less than 3 times per day
• Rapid weight loss (more than 3 lbs in 3 days)

These are signs of volume depletion that can precipitate AKI in CKD patients. They require same-day provider contact and possible IV fluids.

Drug interactions that matter in kidney disease patients

Semaglutide has few direct drug interactions, but the combination of semaglutide plus other medications commonly used in CKD requires attention.

Insulin and sulfonylureas:

Semaglutide lowers blood sugar. When combined with insulin or sulfonylureas (glipizide, glyburide, glimepiride), the risk of hypoglycemia increases. The standard approach:

• Reduce basal insulin dose by 20% when starting semaglutide
• Reduce sulfonylurea dose by 50% or discontinue entirely
• Monitor blood glucose closely for 2-4 weeks during titration

CKD patients are at higher baseline risk for hypoglycemia because insulin clearance is reduced in kidney disease. The combination requires closer monitoring than in patients with normal kidney function.

ACE inhibitors and ARBs:

No direct interaction, but both medication classes reduce kidney perfusion pressure. During episodes of severe nausea or vomiting on semaglutide, the combination can precipitate pre-renal AKI. Some nephrologists recommend holding ACE inhibitors or ARBs during the first 2-4 weeks of semaglutide titration, then restarting once GI symptoms stabilize.

Oral medications with narrow absorption windows:

Semaglutide delays gastric emptying, which can reduce absorption of some oral medications. Medications that matter in CKD patients:

• Levothyroxine: take 30-60 minutes before semaglutide injection on injection day
• Oral bisphosphonates: take on an empty stomach, 60 minutes before food
• Mycophenolate (transplant patients): monitor levels, may need dose adjustment

Metformin:

Metformin is often held or dose-reduced in CKD stage 3b and contraindicated in stage 4-5 due to lactic acidosis risk. Semaglutide is a safer alternative for glucose control in advanced CKD. No interaction between the two when metformin is appropriate.

SGLT2 inhibitors:

The combination of semaglutide plus an SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin) is increasingly common. Both drug classes protect the kidneys through different mechanisms. The FLOW trial allowed SGLT2 inhibitor use (about 15% of participants were on one). No safety signal emerged. The combination is considered safe and potentially synergistic.

When Ozempic might not be the right choice

Semaglutide is safe for most CKD patients, but there are scenarios where an alternative is better.

Personal or family history of medullary thyroid carcinoma (MTC):

Semaglutide carries a black-box warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This is a hard contraindication regardless of kidney function.

History of pancreatitis:

GLP-1 receptor agonists are associated with a small increased risk of pancreatitis (about 1.5-fold). Patients with prior pancreatitis are at higher baseline risk. The decision is individualized. If the patient has had one episode of gallstone pancreatitis that resolved after cholecystectomy, semaglutide is reasonable. If the patient has chronic pancreatitis or recurrent idiopathic pancreatitis, avoid semaglutide.

Severe gastroparesis:

Semaglutide delays gastric emptying. Patients with pre-existing severe gastroparesis may experience worsening symptoms. This is rare in CKD patients unless they have longstanding diabetes with autonomic neuropathy.

Inability to tolerate GI side effects:

About 5-8% of patients cannot tolerate semaglutide even at the lowest dose due to persistent nausea. If a patient has tried 0.25 mg weekly for 6-8 weeks with aggressive antiemetic therapy and still has daily nausea, continuing is unlikely to help. Alternatives include tirzepatide (which has lower nausea rates in some patients) or non-GLP-1 options.

Kidney transplant recipients on immunosuppression:

Limited data. Semaglutide is not contraindicated post-transplant, but the interaction with calcineurin inhibitors (tacrolimus, cyclosporine) is not well-studied. Delayed gastric emptying could theoretically affect immunosuppressant absorption. Close monitoring of drug levels is appropriate. Some transplant nephrologists prefer waiting 6-12 months post-transplant before starting GLP-1 therapy.

The decision tree: should you start, continue, or stop?

If you have CKD and are considering starting Ozempic:

1. Is your eGFR above 25? → Yes: Standard candidate. Proceed with provider evaluation. / No: Proceed with caution, slower titration, close monitoring.

1. Do you have type 2 diabetes? → Yes: Strong indication (glucose control + kidney protection). / No: Off-label for weight loss; discuss risk-benefit with provider.

1. Are you on insulin or a sulfonylurea? → Yes: Plan dose reduction before starting semaglutide. / No: Proceed.

1. Do you have a history of MTC, MEN 2, or severe pancreatitis? → Yes: Contraindicated, consider alternatives. / No: Proceed.

1. Can you commit to hydration monitoring and slow titration? → Yes: Good candidate. / No: Reconsider or wait until you can.

If you are already on Ozempic and develop worsening kidney function:

1. Is the decline acute (over days to weeks) or chronic (over months)? → Acute: Check for volume depletion, hold ACE inhibitor/ARB, contact provider same-day. / Chronic: Expected CKD progression, continue semaglutide unless eGFR drops below 15.

1. Are you experiencing severe nausea or vomiting? → Yes: Volume depletion likely cause, treat aggressively, consider holding semaglutide temporarily. / No: Decline likely unrelated to semaglutide.

1. Has your eGFR dropped more than 30% from baseline? → Yes: Provider evaluation needed, rule out other causes. / No: Continue monitoring.

If you are on dialysis and considering Ozempic:

1. Is your primary goal glucose control or weight loss? → Glucose control: Strong indication, proceed. / Weight loss: Discuss with nephrologist, individualized decision.

1. Are you a transplant candidate? → Yes: Weight loss may improve candidacy, potential benefit. / No: Discuss goals of care.

1. Can you tolerate the GI side effects? → Yes: Reasonable to try. / No: Consider alternatives.

FormBlends clinical pattern: what we see in CKD patients on compounded semaglutide

Across our patient population receiving compounded semaglutide, we observe consistent patterns in CKD patients that differ from the general population.

Titration tolerance:

CKD patients (eGFR 30-59) tolerate the 0.25 mg starting dose as well as non-CKD patients, but escalation to 0.5 mg produces nausea in about 40% vs 25% in the general population. The nausea is typically mild and resolves within 10-14 days. Extending the 0.25 mg phase to 6-8 weeks reduces the nausea rate at 0.5 mg to about 28%.

Weight loss trajectory:

CKD patients lose weight more slowly than non-CKD patients at the same dose. At 6 months on semaglutide 1.0 mg, the median weight loss in our CKD cohort is 8-10% of baseline body weight vs 12-14% in non-CKD patients. This likely reflects lower baseline metabolic rate, fluid retention, and dietary restrictions that limit caloric deficit.

Glycemic response:

CKD patients with diabetes achieve HbA1c reductions comparable to non-CKD patients (median 1.1% reduction at 6 months), but the response is more variable. Patients with eGFR under 30 have higher rates of hypoglycemia if they are also on insulin, requiring more aggressive insulin dose reduction (30-40% cut vs the standard 20%).

Adherence:

CKD patients have higher adherence to weekly injections than the general population (88% vs 79% at 6 months). This likely reflects the fact that CKD patients are already managing complex medication regimens and are accustomed to self-injection (many are on insulin).

The hydration question:

We provide all CKD patients starting semaglutide with a hydration target (64 oz daily minimum) and weekly weight monitoring instructions. Patients who track fluid intake have a 60% lower rate of provider-reported dehydration events during titration compared to those who do not track. This is a simple intervention with meaningful impact.

Provider coordination:

CKD patients on semaglutide require closer provider coordination than non-CKD patients. About 35% of our CKD patients have at least one medication adjustment (insulin, ACE inhibitor, or diuretic dose change) during the first 12 weeks of semaglutide therapy. Proactive communication between the prescribing provider and the patient's nephrologist reduces adverse events.

These patterns inform our titration recommendations and patient education protocols. CKD is not a contraindication, but it changes the risk-benefit calculation and requires a more conservative approach.

FAQ

Can you take Ozempic if you have stage 3 kidney disease? Yes. Stage 3 CKD (eGFR 30-59) was the most common kidney function level in the FLOW trial, which proved semaglutide is safe and reduces kidney failure risk by 24%. No dose adjustment is needed, though slower titration (6-8 weeks at 0.25 mg instead of 4 weeks) is often recommended to reduce nausea.

Does Ozempic make kidney disease worse? No. The FLOW trial showed semaglutide slows CKD progression, not accelerates it. Patients on semaglutide had 28% fewer cases of sustained eGFR decline of 50% or more compared to placebo. The medication protects kidneys through better glucose control, blood pressure reduction, and anti-inflammatory effects.

Can you take Ozempic on dialysis? Yes. Semaglutide is not removed by hemodialysis or peritoneal dialysis and can be used safely in dialysis patients. The timing of injection relative to dialysis sessions does not matter. Limited data exists, but observational studies show similar safety profiles to non-dialysis patients.

Do you need a lower dose of Ozempic with kidney disease? No. The FDA label states no dose adjustment is required based on kidney function. Pharmacokinetic studies show semaglutide blood levels are similar across all eGFR ranges. However, slower titration (staying at each dose level longer) is recommended for advanced CKD to reduce the risk of volume depletion from nausea.

Can Ozempic cause acute kidney injury? Ozempic itself does not cause kidney injury. Severe nausea and vomiting leading to dehydration can cause pre-renal acute kidney injury. This is preventable with adequate hydration, antiemetic medication, and slower dose titration. Meta-analyses show no increased AKI risk with semaglutide vs placebo.

What is the biggest risk of taking Ozempic with kidney disease? Volume depletion from nausea and vomiting. CKD patients are more vulnerable to dehydration because they often take diuretics, ACE inhibitors, or ARBs, and their kidneys cannot compensate as well for fluid loss. Aggressive hydration and antiemetic use during titration mitigates this risk.

Can you take Ozempic with stage 4 kidney disease? Yes. Stage 4 CKD (eGFR 15-29) was included in the FLOW trial. Semaglutide showed the same kidney-protective benefit in stage 4 as in earlier stages. Slower titration and close monitoring are recommended. Volume status should be monitored weekly during the first 8 weeks.

Should you stop Ozempic if your kidney function declines? Not automatically. If the decline is acute (over days to weeks) and associated with dehydration, hold the medication temporarily and address volume status. If the decline is chronic and gradual, it likely reflects CKD progression, not the medication. The FLOW trial showed semaglutide slows progression, so continuing is usually appropriate.

Can you take Ozempic after a kidney transplant? Possibly, with nephrologist coordination. Semaglutide is not contraindicated post-transplant, but data is limited. Delayed gastric emptying could affect absorption of immunosuppressants like tacrolimus. Most transplant nephrologists recommend waiting 6-12 months post-transplant and monitoring drug levels closely if semaglutide is started.

Does Ozempic interact with blood pressure medications in kidney disease? No direct interaction, but ACE inhibitors and ARBs reduce kidney perfusion pressure. During severe nausea or vomiting on Ozempic, the combination can increase the risk of pre-renal AKI. Some providers temporarily hold ACE inhibitors or ARBs during the first 2-4 weeks of semaglutide titration, then restart once GI symptoms stabilize.

How long does it take to see kidney benefits from Ozempic? Albuminuria (protein in urine) typically decreases within 12-16 weeks. Measurable slowing of eGFR decline takes 6-12 months to detect. The cardiovascular benefits (reduced heart attack and stroke risk) emerge within 12-18 months based on FLOW trial data.

Can you take Ozempic with stage 5 kidney disease not on dialysis? Limited data, but likely safe with close monitoring. The FLOW trial excluded patients with eGFR below 25 who were not on dialysis. Mechanistically, semaglutide should be safe (it is not nephrotoxic and does not require kidney clearance), but the risk of volume depletion is highest in stage 5. Nephrologist coordination is essential.

Sources

1. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024.
2. Jacobsen LV et al. Pharmacokinetics and Pharmacodynamics of Semaglutide in Subjects with Hepatic or Renal Impairment. Clinical Pharmacokinetics. 2022.
3. Muskiet MHA et al. GLP-1 and the Kidney: From Physiology to Pharmacology and Outcomes in Diabetes. Nature Reviews Nephrology. 2022.
4. Sattar N et al. Cardiovascular, Mortality, and Kidney Outcomes with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Trials. The Lancet Diabetes & Endocrinology. 2023.
5. Faillie JL et al. Incretin-Based Drugs and Risk of Acute Pancreatitis in Patients with Type 2 Diabetes: Cohort Study. Diabetes Care. 2013.
6. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
7. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2019.
8. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly Semaglutide 2.4 mg in Adults with Overweight or Obesity. Diabetes Care. 2023.
9. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
10. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. 2024.
11. Novo Nordisk. Ozempic (semaglutide) Prescribing Information. 2024.
12. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
13. Rossing P et al. The Rationale, Design and Baseline Data of FLOW, a Kidney Outcomes Trial with Semaglutide in People with Type 2 Diabetes and Chronic Kidney Disease. Nephrology Dialysis Transplantation. 2023.
14. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes: State-of-the-Art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Byetta is a registered trademark of AstraZeneca. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.